- Home
- CNMD vs BLTE Comparison
CNMD vs BLTE Comparison
Compare CNMD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- BLTE
- Stock Information
- Founded
- CNMD 1970
- BLTE 2018
- Country
- CNMD United States
- BLTE United States
- Employees
- CNMD N/A
- BLTE N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- BLTE Health Care
- Exchange
- CNMD Nasdaq
- BLTE Nasdaq
- Market Cap
- CNMD 2.2B
- BLTE 2.1B
- IPO Year
- CNMD 1987
- BLTE 2022
- Fundamental
- Price
- CNMD $58.84
- BLTE $66.70
- Analyst Decision
- CNMD Buy
- BLTE Strong Buy
- Analyst Count
- CNMD 5
- BLTE 4
- Target Price
- CNMD $77.20
- BLTE $96.67
- AVG Volume (30 Days)
- CNMD 488.0K
- BLTE 53.3K
- Earning Date
- CNMD 04-23-2025
- BLTE 03-17-2025
- Dividend Yield
- CNMD 1.36%
- BLTE N/A
- EPS Growth
- CNMD 108.33
- BLTE N/A
- EPS
- CNMD 4.25
- BLTE N/A
- Revenue
- CNMD $1,307,015,000.00
- BLTE N/A
- Revenue This Year
- CNMD $5.97
- BLTE N/A
- Revenue Next Year
- CNMD $5.63
- BLTE N/A
- P/E Ratio
- CNMD $13.85
- BLTE N/A
- Revenue Growth
- CNMD 5.00
- BLTE N/A
- 52 Week Low
- CNMD $55.22
- BLTE $31.01
- 52 Week High
- CNMD $80.65
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- CNMD 42.34
- BLTE 58.99
- Support Level
- CNMD $58.92
- BLTE $64.10
- Resistance Level
- CNMD $61.25
- BLTE $67.40
- Average True Range (ATR)
- CNMD 2.08
- BLTE 2.33
- MACD
- CNMD 0.24
- BLTE -0.33
- Stochastic Oscillator
- CNMD 14.76
- BLTE 37.74
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.